Gilead Sciences Inc. (NASDAQ:GILD) posted upbeat fourth-quarter earnings but issued weak fiscal 2026 guidance on Tuesday.

Gilead reported quarterly earnings of $1.86 per share, which beat the consensus estimate of $1.81, according to data from Benzinga Pro. Quarterly revenue came in at $7.93 billion, which beat the Street estimate of $7.69 billion.

"Our fourth quarter and full-year results close out a very strong year for Gilead overall, including the successful U.S. launch of Yeztugo, the world's first twice-yearly HIV prevention therapy, and continued growth for Biktarvy and Descovy," said CEO Daniel O'Day.

Gilead expects fiscal 2026 adjusted EPS of $8.45 to $8.85, versus the $8.74 analyst estimate, and revenue in a range of $29.6 billion to $30 billion, versus the $30.22 billion estimate.

Gilead shares fell 1.8% to $144.55 in pre-market trading.

These analysts made changes to their price targets on Gilead following earnings announcement.

• Needham analyst Joseph Stringer maintained Gilead with a Buy and raised the price target from $140 to $170.
• Scotiabank analyst Louis Chen maintained the stock with a Sector Outperform and raised the price target from $140 to $177.
• Cantor Fitzgerald analyst Carter Gould maintained Gilead Sciences with an Overweight rating and raised the price target from $135 to $155.

Considering buying GILD stock? Here’s what analysts think:

Photo via Shutterstock